AR082436A1 - Uso de teriflunomida para tratar la esclerosis multiple - Google Patents

Uso de teriflunomida para tratar la esclerosis multiple

Info

Publication number
AR082436A1
AR082436A1 ARP110102772A ARP110102772A AR082436A1 AR 082436 A1 AR082436 A1 AR 082436A1 AR P110102772 A ARP110102772 A AR P110102772A AR P110102772 A ARP110102772 A AR P110102772A AR 082436 A1 AR082436 A1 AR 082436A1
Authority
AR
Argentina
Prior art keywords
teriflunomide
multiple sclerosis
treat multiple
treat
treatment
Prior art date
Application number
ARP110102772A
Other languages
English (en)
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of AR082436A1 publication Critical patent/AR082436A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Uso de teriflunomida para el tratamiento de la Esclerosis Múltiple (EM) y para tratar los riesgos asociados con el uso de teriflunomida.
ARP110102772A 2010-08-02 2011-08-01 Uso de teriflunomida para tratar la esclerosis multiple AR082436A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36978010P 2010-08-02 2010-08-02
US36977910P 2010-08-02 2010-08-02
US38937510P 2010-10-04 2010-10-04
US201061424717P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
AR082436A1 true AR082436A1 (es) 2012-12-05

Family

ID=45559773

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102772A AR082436A1 (es) 2010-08-02 2011-08-01 Uso de teriflunomida para tratar la esclerosis multiple

Country Status (4)

Country Link
EP (1) EP2600861A1 (es)
AR (1) AR082436A1 (es)
UY (1) UY33542A (es)
WO (1) WO2012018704A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2762135A1 (en) * 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
KR20220166827A (ko) * 2020-04-09 2022-12-19 노파르티스 아게 혈청 IgG를 유지하면서 MS를 치료하기 위한 오파투무맙

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis

Also Published As

Publication number Publication date
UY33542A (es) 2012-02-29
EP2600861A1 (en) 2013-06-12
WO2012018704A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
ECSP15026557A (es) Compuestos y sus métodos de empleo
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
AR089993A1 (es) Macrociclos peptidomimeticos
CO7020872A2 (es) Agentes de arn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
CL2012003385A1 (es) Tratamiento para la incontinencia.
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
NI201400042A (es) 2 - tiopirimidinonas
CO7350653A2 (es) Retinoides y uso de los mismos
EA201591399A1 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
UY34315A (es) ?uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas ?
MX369290B (es) Inhibidores de fbx03.
AR082436A1 (es) Uso de teriflunomida para tratar la esclerosis multiple
UY35823A (es) Profármacos de antagonista de nmda
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
CO7121349A2 (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
AR081220A1 (es) Uso de teriflunomida para el tratamiento de la atrofia cerebral
MX2013006526A (es) Dosis de los derivados de arilsulfonamida.
CR20140489A (es) Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t

Legal Events

Date Code Title Description
FB Suspension of granting procedure